Oxygen4Life™, Inc. CEO Mike Maunu - Presenting To The "Global Capital Network" Event In Newport Beach, CA - 06/28/2023

Presentation Transcripts & Cliff-Notes

Introduction

Welcome to Oxygen4Life™, Inc. where we redefine the approach to cardiovascular health and chronic inflammation. We present a groundbreaking, non-invasive test that takes just a minute, coupled with a patented, plant-based solution that's clinically proven to work wonders. All of this is available over the counter and through medical practitioners, making it a truly accessible solution.

The Market

Despite the billions spent on pharmaceuticals and supplements, the health crisis persists, creating a burgeoning market for wellness devices. However, many of these devices, like pulse oximeters, offer a limited view of one's internal health. This is where our solution steps in, offering a comprehensive, in-depth insight into your health.

The Drive To Deliver A Solution

Our solution is a testament to two decades of relentless research and development. We're currently amidst an SEC-registered raise, with our primary focus on combating the silent menace of chronic inflammation that often leads to heart disease, the world's leading cause of death.

Our Solution: Medical & Wellness Devices

We offer two distinct devices: an FDA-cleared Class II medical device that measures the risk of cardiovascular disease and chronic inflammation, and a personal wellness device designed for home use. The results from the personal device can be easily shared with your healthcare practitioner, fostering a collaborative approach to health management.

Our Solution: Organic, Cold-Pressed, Unadulterated Products

Our patented products, derived from unadulterated oils, serve as the building blocks for the body's cells. Clinically validated to reverse cardiovascular aging and plaque buildup in arteries in as little as 90 days, they are a game-changer. We also offer a patented medical food, available exclusively through an MD, that can treat 13 major diseases.

The Impact

Endorsed by medical professionals and validated in independent studies, our solution is making waves in the healthcare industry. Early detection, consistent monitoring, lifestyle changes, and products that address the root cause – that's our comprehensive answer to the health crisis.

Our Business

We're not seeking funds to create or patent a device – we've already done that. We're seeking fuel for our marketing engine, to onboard a sales team that will engage with doctors and practitioners. Our team is a powerhouse of experience and expertise in diverse fields, including digital media and business coaching.

Our Strategy

Our strategy is rooted in independent direct sales, backed by our patented and approved medical devices. Our distribution strategy spans B2C and more. We're also in advanced discussions with a medical device company that sells into the GSA and the VA with the government. We have three distinct revenue streams: medical device sales and leasing, product sales for annual recurring revenue, and training certification fees from our sales agents and practitioners.

Conclusion

Our focus is on cardiovascular disease and chronic inflammation. With everything in place, we're poised to become the category king. Our goal is to change the standard of care and make a difference in the world today, not just for the older generation but for our children and grandchildren as well. Visit our website or contact us to start your journey to a healthier heart today.

Take Control of Your Health Today

We invite you to explore our range of products and services, and join us in our mission to revolutionize the approach to cardiovascular health. Your journey to a healthier heart starts today with Oxygen4Life™, Inc. 
Copyrights 2024 | All Rights Reserved | Oxygen4life.com | Oxygen4Life Inc™
PRIVACY POLICY -  TERMS & CONDITIONS - BLOG
These statements have not been evaluated by the Food and Drug Administration. These products and statements are not intended to diagnose, treat, cure or prevent any disease or illness. These statements should not be taken as medical advice, you should always consult your doctor before making any health changes, decisions and/or drawing any health conclusions. 

This site is not a part of the Facebook website or Facebook Inc. Additionally, This site is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.
1. E. Wainwright, Y. S. Huang, et al., “The Effects of Dietary n-3/n-6 Ratio on Brain Development in the Mouse: A Dose Response Study with Long-Chain n-3 Fatty Acids,” Lipids, vol. 27, no. 2, pp. 98-103, 1992; W. E. M. Lands, et al., “Quantitative effects of dietary polyunsaturated fats on the composition of fatty acids in rat tissues,” Lipids, vol. 25, no. 9, pp. 505-516, 1990.

2. C. V. Felton, et al., “Relation of Plaque Lipid Composition and Morphology to the Stability of Human Aortic Plaques,”
Arteriosclerosis, Thrombosis, and Vascular Biology,” Vol. 17, No 7, 1997, pp. 1337-1345.
Oxygen4Life, Inc. is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Title III of the JOBS Act and Regulation CF. A copy of the Form C that forms a part of the Offering Statement may be obtained from: Form C

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 105 Maxess Road, Suite 124, Melville, NY 11747, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck. DealMaker Securities LLC does not make investment recommendations. DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer. DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment. DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing. DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself. Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.